Focus
Paxlovid
FDA Revises Emergency Use of Paxlovid
The revision is a step toward finalizing the transition from Paxlovid’s emergency use authorization to its new drug application label, initiated in late 2023.
How the COVID Virus Defends Itself From the Human Immune System
Researchers believe they’ve identified the mechanisms that allow the SARS-CoV-2 virus to be so effective at making us sick.
Paxlovid Doesn’t Reduce Risk of Long COVID, Potentially Linked to Rebound Symptoms: Study
Researchers found little difference in outcomes between Paxlovid users and nonusers. They also found 1 in 5 users experienced rebound symptoms.
FDA Approved Nearly 50 Percent More Drugs in 2023 Than in 2022
Only 2018 featured a higher number of drug approvals.
One in Five Pfizer Drug Users Experience COVID-19 Rebound: Study
Many Paxlovid recipients have suffered from renewed symptoms.
Paxlovid Does Not Work Against ‘Long COVID’: Study
Out of the 31 long COVID conditions, Paxlovid was found to minimize the incidence of only one.
Pfizer to Charge Nearly $1,400 for COVID-19 Drug Paxlovid
Pfizer projects Paxlovid sales to fall by 58 percent this year compared to 2022.
Study Finds Paxlovid, Molnupiravir Reduce Omicron Hospitalization, Mortality
Researchers said that both oral antiviral drugs can be used to treat nonhospitalized patients at high risk of progressing to severe COVID-19.
